ADVM-022 Emerging Drug Insight

“ADVM-022 Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about ADVM-022 for Diabetic Retinopathy in the seven major markets. A detailed picture of the ADVM-022 for diabetic retinopathy in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the ADVM-022 for diabetic retinopathy. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ADVM-022 market forecast analysis for diabetic retinopathy in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in diabetic retinopathy.

Drug Summary

ADVM-022 utilizes a propriety vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette. ADVM-022 is administered as a one-time intravitreal injection (IVT), designed to deliver long-term efficacy and reduce the burden of frequent anti-VEGF injections, optimize patient compliance and improve vision outcomes for patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

The AAV.7m8 capsid was engineered from AAV2 by directed evolution to transduce retinal cells following intravitreal injection efficiently. The vector carries a vector genome (“vg”) encoding a codon-optimized cDNA of the aflibercept protein, a current standard of care in wet AMD, under the control of a strong, ubiquitous expression cassette.

Maintaining consistent levels of VEGF suppression with ADVM-022 could be particularly important for this rapidly-progressing disease. The current standard-of-care therapy for diabetic retinopathy is anti-VEGF intravitreal (“IVT”) injections. These are effective but typically require eye injections every 4-12 weeks to maintain vision. Compliance with this regimen can be difficult for patients, caregivers, and healthcare systems, leading to under treatment and resulting in loss of vision.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the ADVM-022 description, mechanism of action, dosage and administration, research and development activities in diabetic retinopathy.
• Elaborated details on ADVM-022 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ADVM-022 research and development activities in diabetic retinopathy across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around ADVM-022.
• The report contains forecasted sales of for diabetic retinopathy till 2032.
• Comprehensive coverage of the late-stage emerging therapies for diabetic retinopathy.
• The report also features the SWOT analysis with analyst views for ADVM-022 in diabetic retinopathy.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ADVM-022 Analytical Perspective by DelveInsight

• In-depth ADVM-022 Market Assessment

This report provides a detailed market assessment of ADVM-022 for diabetic retinopathy in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.

• ADVM-022 Clinical Assessment

The report provides the clinical trials information of ADVM-022 for diabetic retinopathy covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for diabetic retinopathy is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ADVM-022 dominance.
• Other emerging products for diabetic retinopathy are expected to give tough market competition to ADVM-022 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ADVM-022 in diabetic retinopathy.
• Our in-depth analysis of the forecasted sales data of ADVM-022 from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ADVM-022 in diabetic retinopathy.

Key Questions

• What is the product type, route of administration and mechanism of action of ADVM-022?
• What is the clinical trial status of the study related to ADVM-022 in diabetic retinopathy and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ADVM-022 development?
• What are the key designations that have been granted to ADVM-022 for diabetic retinopathy?
• What is the forecasted market scenario of ADVM-022 for diabetic retinopathy?
• What are the forecasted sales of ADVM-022 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available and how are these giving competition to ADVM-022 for diabetic retinopathy?
• Which are the late-stage emerging therapies under development for the treatment of diabetic retinopathy?